Mefenamic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mefenamic acid" in English language version.

Last modified: 02:21:04, 16 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

2924nih.gov

5^th place

2120doi.org

2^nd place

87semanticscholar.org

15^th place

8^th place

64fda.gov

470^th place

329^th place

52drugs.com

529^th place

550^th place

32web.archive.org

1^st place

31mediq.ch

low place

22worldcat.org

4^th place

22adsabs.harvard.edu

14^th place

9^th place

22medicinescomplete.com

low place

21rushim.ru

low place

11tga.gov.au

4,353^rd place

2,806^th place

11canada.ca

1,114^th place

605^th place

11nihr.ac.uk

low place

7,409^th place

11medlineplus.gov

1,521^st place

1,017^th place

11ipc.gov.in

low place

11google.com

109^th place

87^th place

11pharmac.govt.nz

low place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Belov KV, Batista de Carvalho LA, Dyshin AA, Kiselev MG, Sobornova VV, Khodov IA (December 2022). "Conformational Analysis of Mefenamic Acid in scCO2-DMSO by the 2D NOESY Method". Russian Journal of Physical Chemistry B. 16 (7): 1191–1199. Bibcode:2022RJPCB..16.1191B. doi:10.1134/S1990793122070028. ISSN 1990-7931. S2CID 256259116.
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. (August 2016). "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models". Nature Communications. 7 12504. Bibcode:2016NatCo...712504D. doi:10.1038/ncomms12504. PMC 4987536. PMID 27509875.

canada.ca (Global: 1,114^th place; English: 605^th place)

"Product monograph brand safety updates". Health Canada. 6 June 2024. Retrieved 8 June 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Pringsheim T, Davenport WJ, Dodick D (April 2008). "Acute treatment and prevention of menstrually related migraine headache: evidence-based review". Neurology. 70 (17): 1555–1563. doi:10.1212/01.wnl.0000310638.54698.36. PMID 18427072. S2CID 27966664.
"Digital Medicines Information Suite". MedicinesComplete. doi:10.18578/bnf.855907230. Retrieved 2020-04-18.
Kai J, Dutton B, Vinogradova Y, Hilken N, Gupta J, Daniels J (October 2023). "Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study". Health Technology Assessment. 27 (17): 1–50. doi:10.3310/JHSW0174. PMC 10641716. PMID 37924269.
"The coil and medicines are both effective long-term treatments for heavy periods". NIHR Evidence. 8 March 2024. doi:10.3310/nihrevidence_62335.
Prusakiewicz JJ, Duggan KC, Rouzer CA, Marnett LJ (August 2009). "Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid". Biochemistry. 48 (31): 7353–7355. doi:10.1021/bi900999z. PMC 2720641. PMID 19603831.
Whitehouse MW (2009). "Drugs to treat inflammation: a historical introduction". Current Medicinal Chemistry. 4 (25): 707–729 (718). doi:10.2174/092986705774462879. ISBN 978-1-60805-207-3. PMID 16378496.{{cite journal}}: CS1 maint: periodical has ISBN (link)
Trinus FP, Mokhort NA, Yagupol'skii LM, Fadeicheva AG, Danilenko VS, Ryabukha TK, et al. (1977). "Mefenamic acid — A Nonsteroid Antiinflammatory Agent". Pharmaceutical Chemistry Journal. 11 (12): 1706–1711. doi:10.1007/BF00778304. S2CID 45211486.
SeethaLekshmi S, Guru Row TN (August 2012). "Conformational Polymorphism in a Non-steroidal Anti-inflammatory Drug, Mefenamic Acid". Crystal Growth & Design. 12 (8): 4283–4289. doi:10.1021/cg300812v. ISSN 1528-7483.
Belov KV, Batista de Carvalho LA, Dyshin AA, Efimov SV, Khodov IA (October 2022). "The Role of Hidden Conformers in Determination of Conformational Preferences of Mefenamic Acid by NOESY Spectroscopy". Pharmaceutics. 14 (11): 2276. doi:10.3390/pharmaceutics14112276. PMC 9696638. PMID 36365095.
Khodov IA, Belov KV, Efimov SV, de Carvalho LA (January 2019). Determination of preferred conformations of mefenamic acid in DMSO by NMR spectroscopy and GIAO calculation. AIP Conference Proceedings. Vol. 2063. AIP Publishing. p. 040007. doi:10.1063/1.5087339.
Belov KV, Batista de Carvalho LA, Dyshin AA, Kiselev MG, Sobornova VV, Khodov IA (December 2022). "Conformational Analysis of Mefenamic Acid in scCO2-DMSO by the 2D NOESY Method". Russian Journal of Physical Chemistry B. 16 (7): 1191–1199. Bibcode:2022RJPCB..16.1191B. doi:10.1134/S1990793122070028. ISSN 1990-7931. S2CID 256259116.
Khodov I, Sobornova V, Mulloyarova V, Belov K, Dyshin A, de Carvalho LB, et al. (August 2023). "Does DMSO affect the conformational changes of drug molecules in supercritical CO2 Media?". Journal of Molecular Liquids. 384 122230. doi:10.1016/j.molliq.2023.122230. S2CID 259822531.
Khodov I, Sobornova V, Mulloyarova V, Belov K, Dyshin A, de Carvalho LB, et al. (April 2023). "Exploring the Conformational Equilibrium of Mefenamic Acid Released from Silica Aerogels via NMR Analysis". International Journal of Molecular Sciences. 24 (8): 6882. doi:10.3390/ijms24086882. PMC 10138679. PMID 37108046.
Khodov IA, Musabirova GS, Klochkov VV, Karataeva FK, Huster D, Scheidt HA (December 2022). "Structural details on the interaction of fenamates with lipid membranes". Journal of Molecular Liquids. 367 120502. doi:10.1016/j.molliq.2022.120502. S2CID 252747244.
Khodov IA, Belov KV, Huster D, Scheidt HA (June 2023). "Conformational State of Fenamates at the Membrane Interface: A MAS NOESY Study". Membranes. 13 (6): 607. doi:10.3390/membranes13060607. PMC 10300900. PMID 37367811.
Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, et al. (January 2006). "Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models". Molecular Pharmacology. 69 (1): 76–84. doi:10.1124/mol.105.015206. PMID 16223958. S2CID 20982844.
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. (August 2016). "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models". Nature Communications. 7 12504. Bibcode:2016NatCo...712504D. doi:10.1038/ncomms12504. PMC 4987536. PMID 27509875.
Miguel-Álvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, et al. (February 2015). "Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect". Drugs & Aging. 32 (2): 139–147. doi:10.1007/s40266-015-0239-z. PMID 25644018. S2CID 35357112.
Jaturapatporn D, Isaac MG, McCleery J, Tabet N (February 2012). "Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease". The Cochrane Database of Systematic Reviews (2) CD006378. doi:10.1002/14651858.CD006378.pub2. PMC 11337172. PMID 22336816.
Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. (2015). "Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis". Journal of Alzheimer's Disease. 44 (2): 385–396. doi:10.3233/JAD-141506. PMID 25227314.

drugs.com (Global: 529^th place; English: 550^th place)

"International listings for mefenamic acid". Drugs.com. Retrieved 3 July 2015.
Cerner Multum. "Mefenamic Acid". Drugs.com. Retrieved 2020-07-22.

fda.gov (Global: 470^th place; English: 329^th place)

fda.gov

"Safety Labeling Changes: Ponstel (mefenamic acid capsules, USP)". Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration. March 2008. Archived from the original on 4 November 2009.
"FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020.^{[dead link]} This article incorporates text from this source, which is in the public domain.
"NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Ponstel Label" (PDF). U.S. Food and Drug Administration. 19 February 2008.

google.com (Global: 109^th place; English: 87^th place)

US 3,138,636, Scherrer RA, issued 23 June 1964, assigned to Parke Davis and Co LLC

ipc.gov.in (Global: low place; English: low place)

"Monthly Drug Safety Alert". Indian Pharmacopoeia Commission. 30 November 2023. Retrieved 10 December 2023.

medicinescomplete.com (Global: low place; English: low place)

about.medicinescomplete.com

"Digital Medicines Information Suite". MedicinesComplete. doi:10.18578/bnf.855907230. Retrieved 2020-04-18.

medicinescomplete.com

"Access leading drug and healthcare references". www.medicinescomplete.com. Retrieved 19 September 2014..

mediq.ch (Global: low place; English: low place)

"mediQ: Mefenaminsäure". Retrieved 2020-07-23.

medlineplus.gov (Global: 1,521^st place; English: 1,017^th place)

"Side effects for Mefenamic Acid". Medline Plus. National Institutes of Health.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Pringsheim T, Davenport WJ, Dodick D (April 2008). "Acute treatment and prevention of menstrually related migraine headache: evidence-based review". Neurology. 70 (17): 1555–1563. doi:10.1212/01.wnl.0000310638.54698.36. PMID 18427072. S2CID 27966664.
Kai J, Dutton B, Vinogradova Y, Hilken N, Gupta J, Daniels J (October 2023). "Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study". Health Technology Assessment. 27 (17): 1–50. doi:10.3310/JHSW0174. PMC 10641716. PMID 37924269.
"Mefenamic Acid". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. January 2020. PMID 31643361. Retrieved 28 November 2019.
Prusakiewicz JJ, Duggan KC, Rouzer CA, Marnett LJ (August 2009). "Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid". Biochemistry. 48 (31): 7353–7355. doi:10.1021/bi900999z. PMC 2720641. PMID 19603831.
Whitehouse MW (2009). "Drugs to treat inflammation: a historical introduction". Current Medicinal Chemistry. 4 (25): 707–729 (718). doi:10.2174/092986705774462879. ISBN 978-1-60805-207-3. PMID 16378496.{{cite journal}}: CS1 maint: periodical has ISBN (link)
Belov KV, Batista de Carvalho LA, Dyshin AA, Efimov SV, Khodov IA (October 2022). "The Role of Hidden Conformers in Determination of Conformational Preferences of Mefenamic Acid by NOESY Spectroscopy". Pharmaceutics. 14 (11): 2276. doi:10.3390/pharmaceutics14112276. PMC 9696638. PMID 36365095.
Khodov I, Sobornova V, Mulloyarova V, Belov K, Dyshin A, de Carvalho LB, et al. (April 2023). "Exploring the Conformational Equilibrium of Mefenamic Acid Released from Silica Aerogels via NMR Analysis". International Journal of Molecular Sciences. 24 (8): 6882. doi:10.3390/ijms24086882. PMC 10138679. PMID 37108046.
Khodov IA, Belov KV, Huster D, Scheidt HA (June 2023). "Conformational State of Fenamates at the Membrane Interface: A MAS NOESY Study". Membranes. 13 (6): 607. doi:10.3390/membranes13060607. PMC 10300900. PMID 37367811.
"Drugs for Osteoarthritis". The Medical Letter. 56 (1450): 80–84. September 2014. PMID 25157683.
Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, et al. (January 2006). "Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models". Molecular Pharmacology. 69 (1): 76–84. doi:10.1124/mol.105.015206. PMID 16223958. S2CID 20982844.
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. (August 2016). "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models". Nature Communications. 7 12504. Bibcode:2016NatCo...712504D. doi:10.1038/ncomms12504. PMC 4987536. PMID 27509875.
Miguel-Álvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, et al. (February 2015). "Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect". Drugs & Aging. 32 (2): 139–147. doi:10.1007/s40266-015-0239-z. PMID 25644018. S2CID 35357112.
Jaturapatporn D, Isaac MG, McCleery J, Tabet N (February 2012). "Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease". The Cochrane Database of Systematic Reviews (2) CD006378. doi:10.1002/14651858.CD006378.pub2. PMC 11337172. PMID 22336816.
Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. (2015). "Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis". Journal of Alzheimer's Disease. 44 (2): 385–396. doi:10.3233/JAD-141506. PMID 25227314.
Melnikov V, Tiburcio-Jimenez D, Mendoza-Hernandez MA, Delgado-Enciso J, De-Leon-Zaragoza L, Guzman-Esquivel J, et al. (2021). "Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy". American Journal of Translational Research. 13 (5): 4535–4543. PMC 8205720. PMID 34150033.

ncbi.nlm.nih.gov

Kai J, Dutton B, Vinogradova Y, Hilken N, Gupta J, Daniels J (October 2023). "Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study". Health Technology Assessment. 27 (17): 1–50. doi:10.3310/JHSW0174. PMC 10641716. PMID 37924269.
"Mefenamic Acid". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. January 2020. PMID 31643361. Retrieved 28 November 2019.
Prusakiewicz JJ, Duggan KC, Rouzer CA, Marnett LJ (August 2009). "Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid". Biochemistry. 48 (31): 7353–7355. doi:10.1021/bi900999z. PMC 2720641. PMID 19603831.
Belov KV, Batista de Carvalho LA, Dyshin AA, Efimov SV, Khodov IA (October 2022). "The Role of Hidden Conformers in Determination of Conformational Preferences of Mefenamic Acid by NOESY Spectroscopy". Pharmaceutics. 14 (11): 2276. doi:10.3390/pharmaceutics14112276. PMC 9696638. PMID 36365095.
Khodov I, Sobornova V, Mulloyarova V, Belov K, Dyshin A, de Carvalho LB, et al. (April 2023). "Exploring the Conformational Equilibrium of Mefenamic Acid Released from Silica Aerogels via NMR Analysis". International Journal of Molecular Sciences. 24 (8): 6882. doi:10.3390/ijms24086882. PMC 10138679. PMID 37108046.
Khodov IA, Belov KV, Huster D, Scheidt HA (June 2023). "Conformational State of Fenamates at the Membrane Interface: A MAS NOESY Study". Membranes. 13 (6): 607. doi:10.3390/membranes13060607. PMC 10300900. PMID 37367811.
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. (August 2016). "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models". Nature Communications. 7 12504. Bibcode:2016NatCo...712504D. doi:10.1038/ncomms12504. PMC 4987536. PMID 27509875.
Jaturapatporn D, Isaac MG, McCleery J, Tabet N (February 2012). "Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease". The Cochrane Database of Systematic Reviews (2) CD006378. doi:10.1002/14651858.CD006378.pub2. PMC 11337172. PMID 22336816.
Melnikov V, Tiburcio-Jimenez D, Mendoza-Hernandez MA, Delgado-Enciso J, De-Leon-Zaragoza L, Guzman-Esquivel J, et al. (2021). "Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy". American Journal of Translational Research. 13 (5): 4535–4543. PMC 8205720. PMID 34150033.

nihr.ac.uk (Global: low place; English: 7,409^th place)

evidence.nihr.ac.uk

"The coil and medicines are both effective long-term treatments for heavy periods". NIHR Evidence. 8 March 2024. doi:10.3310/nihrevidence_62335.

pharmac.govt.nz (Global: low place; English: low place)

schedule.pharmac.govt.nz

"PHARMAC Schedule Online". schedule.pharmac.govt.nz. Retrieved 22 October 2024.

rushim.ru (Global: low place; English: low place)

files.rushim.ru

Sittig M (1988). "Mefenamic acid". Pharmaceutical Manufacturing Encyclopedia (PDF). Vol. 1 (Second ed.). Noyes Publications. pp. 918–919. Archived from the original (PDF) on 2007-10-23.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Pringsheim T, Davenport WJ, Dodick D (April 2008). "Acute treatment and prevention of menstrually related migraine headache: evidence-based review". Neurology. 70 (17): 1555–1563. doi:10.1212/01.wnl.0000310638.54698.36. PMID 18427072. S2CID 27966664.
Trinus FP, Mokhort NA, Yagupol'skii LM, Fadeicheva AG, Danilenko VS, Ryabukha TK, et al. (1977). "Mefenamic acid — A Nonsteroid Antiinflammatory Agent". Pharmaceutical Chemistry Journal. 11 (12): 1706–1711. doi:10.1007/BF00778304. S2CID 45211486.
Belov KV, Batista de Carvalho LA, Dyshin AA, Kiselev MG, Sobornova VV, Khodov IA (December 2022). "Conformational Analysis of Mefenamic Acid in scCO2-DMSO by the 2D NOESY Method". Russian Journal of Physical Chemistry B. 16 (7): 1191–1199. Bibcode:2022RJPCB..16.1191B. doi:10.1134/S1990793122070028. ISSN 1990-7931. S2CID 256259116.
Khodov I, Sobornova V, Mulloyarova V, Belov K, Dyshin A, de Carvalho LB, et al. (August 2023). "Does DMSO affect the conformational changes of drug molecules in supercritical CO2 Media?". Journal of Molecular Liquids. 384 122230. doi:10.1016/j.molliq.2023.122230. S2CID 259822531.
Khodov IA, Musabirova GS, Klochkov VV, Karataeva FK, Huster D, Scheidt HA (December 2022). "Structural details on the interaction of fenamates with lipid membranes". Journal of Molecular Liquids. 367 120502. doi:10.1016/j.molliq.2022.120502. S2CID 252747244.
Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, et al. (January 2006). "Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models". Molecular Pharmacology. 69 (1): 76–84. doi:10.1124/mol.105.015206. PMID 16223958. S2CID 20982844.
Miguel-Álvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, et al. (February 2015). "Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect". Drugs & Aging. 32 (2): 139–147. doi:10.1007/s40266-015-0239-z. PMID 25644018. S2CID 35357112.

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

"Safety Labeling Changes: Ponstel (mefenamic acid capsules, USP)". Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration. March 2008. Archived from the original on 4 November 2009.
Sittig M (1988). "Mefenamic acid". Pharmaceutical Manufacturing Encyclopedia (PDF). Vol. 1 (Second ed.). Noyes Publications. pp. 918–919. Archived from the original (PDF) on 2007-10-23.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

SeethaLekshmi S, Guru Row TN (August 2012). "Conformational Polymorphism in a Non-steroidal Anti-inflammatory Drug, Mefenamic Acid". Crystal Growth & Design. 12 (8): 4283–4289. doi:10.1021/cg300812v. ISSN 1528-7483.
Belov KV, Batista de Carvalho LA, Dyshin AA, Kiselev MG, Sobornova VV, Khodov IA (December 2022). "Conformational Analysis of Mefenamic Acid in scCO2-DMSO by the 2D NOESY Method". Russian Journal of Physical Chemistry B. 16 (7): 1191–1199. Bibcode:2022RJPCB..16.1191B. doi:10.1134/S1990793122070028. ISSN 1990-7931. S2CID 256259116.

Mefenamic acid (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

canada.ca (Global: 1,114th place; English: 605th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

fda.gov (Global: 470th place; English: 329th place)

fda.gov

accessdata.fda.gov

google.com (Global: 109th place; English: 87th place)

ipc.gov.in (Global: low place; English: low place)

medicinescomplete.com (Global: low place; English: low place)

about.medicinescomplete.com

medicinescomplete.com

mediq.ch (Global: low place; English: low place)

medlineplus.gov (Global: 1,521st place; English: 1,017th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nihr.ac.uk (Global: low place; English: 7,409th place)

evidence.nihr.ac.uk

pharmac.govt.nz (Global: low place; English: low place)

schedule.pharmac.govt.nz

rushim.ru (Global: low place; English: low place)

files.rushim.ru

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

canada.ca (Global: 1,114^th place; English: 605^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

fda.gov (Global: 470^th place; English: 329^th place)

google.com (Global: 109^th place; English: 87^th place)

medlineplus.gov (Global: 1,521^st place; English: 1,017^th place)

nih.gov (Global: 5^th place; English: 5^th place)

nihr.ac.uk (Global: low place; English: 7,409^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 4^th place; English: 4^th place)